CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project evaluates a novel peptide as a treatment for multiple sclerosis (MS), aiming to halt disease progression and promote tissue regeneration. The peptide's unique properties may offer a cost-effective and less invasive alternative to current therapies.
REGENERA MS will assess the technical and commercial feasibility of a novel peptide as a superior treatment for multiple sclerosis (MS).
Successful commercialization of our peptide could reduce the socioeconomic burden of MS, provide an early-therapy option to delay disease progression and thus extend and improve patients lives, with potential effectiveness in related neurodegenerative diseases. MS is a chronic inflammatory, autoimmune, and neurological disease without a cure, affecting the live…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
